PTC
DGX icon

Philadelphia Trust Company’s Quest Diagnostics DGX Stock Holding History

Philadelphia Trust Company’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,329
Closed -$597K – 240
2023
Q4 		$597K Sell
4,329
-945
-18% -$124K 0.06% 140
2023
Q3 		$643K Sell
5,274
-735
-12% -$97.9K 0.07% 132
2023
Q2 		$845K Sell
6,009
-535
-8% -$73.8K 0.08% 125
2023
Q1 		$926K Sell
6,544
-238
-4% -$34K 0.09% 122
2022
Q4 		$1.06M Sell
6,782
-110
-2% -$15.8K 0.11% 113
2022
Q3 		$846K Sell
6,892
-270
-4% -$35.6K 0.1% 115
2022
Q2 		$952K Sell
7,162
-1,650
-19% -$225K 0.1% 110
2022
Q1 		$1.21M Sell
8,812
-50
-0.6% -$6.97K 0.1% 109
2021
Q4 		$1.53M Sell
8,862
-125
-1% -$19K 0.11% 101
2021
Q3 		$1.31M Sell
8,987
-15
-0.2% -$2.19K 0.1% 114
2021
Q2 		$1.19M Sell
9,002
-276
-3% -$36.1K 0.08% 126
2021
Q1 		$1.19M Buy
9,278
+140
+2% +$17.3K 0.09% 121
2020
Q4 		$1.09M Buy
9,138
+455
+5% +$55.5K 0.09% 116
2020
Q3 		$994K Buy
8,683
+400
+5% +$47.3K 0.1% 111
2020
Q2 		$944K Sell
8,283
-100
-1% -$10.6K 0.1% 101
2020
Q1 		$673K Sell
8,383
-165
-2% -$17.1K 0.08% 103
2019
Q4 		$913K Sell
8,548
-5
-0.1% -$521 0.08% 120
2019
Q3 		$915K Sell
8,553
-100
-1% -$10.3K 0.08% 123
2019
Q2 		$881K Sell
8,653
-1,459
-14% -$140K 0.08% 130
2019
Q1 		$909K Sell
10,112
-1,139
-10% -$98.7K 0.08% 124
2018
Q4 		$937K Sell
11,251
-620
-5% -$58.1K 0.1% 104
2018
Q3 		$1.28M Sell
11,871
-405
-3% -$44.4K 0.11% 106
2018
Q2 		$1.35M Sell
12,276
-195
-2% -$20.3K 0.12% 101
2018
Q1 		$1.25M Sell
12,471
-1,170
-9% -$120K 0.1% 109
2017
Q4 		$1.34M Sell
13,641
-12,112
-47% -$1.15M 0.11% 113
2017
Q3 		$2.41M Sell
25,753
-445
-2% -$47.2K 0.2% 84
2017
Q2 		$2.91M Sell
26,198
-187
-0.7% -$19.8K 0.25% 79
2017
Q1 		$2.59M Sell
26,385
-157,260
-86% -$15M 0.21% 84
2016
Q4 		$16.9M Sell
183,645
-31,115
-14% -$2.68M 1.35% 29
2016
Q3 		$18.2M Sell
214,760
-92,425
-30% -$7.76M 1.57% 22
2016
Q2 		$25M Sell
307,185
-62,170
-17% -$4.73M 2.16% 11
2016
Q1 		$26.4M Sell
369,355
-2,050
-0.6% -$137K 2.26% 13
2015
Q4 		$26.1M Buy
371,405
+35,374
+11% +$2.38M 2.19% 13
2015
Q3 		$20.7M Buy
336,031
+313,215
+1,373% +$21.9M 1.87% 19
2015
Q2 		$315K Sell
22,816
-229,362
-91% -$16.9M 1.16% 28
2015
Q1 		$19.4M Buy
252,178
+22,530
+10% +$1.61M 1.48% 27
2014
Q4 		$15.4M Sell
229,648
-120,195
-34% -$7.58M 1.24% 38
2014
Q3 		$21.2M Sell
349,843
-4,102
-1% -$253K 1.32% 39
2014
Q2 		$20.8M Sell
353,945
-19,770
-5% -$1.16M 1.29% 39
2014
Q1 		$21.6M Buy
373,715
+7,455
+2% +$400K 1.36% 40
2013
Q4 		$19.6M Sell
366,260
-41,937
-10% -$2.49M 1.25% 41
2013
Q3 		$25.2M Sell
408,197
-423
-0.1% -$25.3K 1.74% 27
2013
Q2 		$24.8M Buy
+408,620
New +$24.3M 1.86% 29

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Philadelphia Trust Company's DGX Position: Q1 2024 in Review

Philadelphia Trust Company sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 4,329 shares — an estimated $597K sold.

Philadelphia Trust Company first reported a position in DGX in Q2 2013 and held it in 43 quarters. The position peaked at $26.4M in Q1 2016. 818 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

  • Philadelphia Trust Company reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Philadelphia Trust Company sold 4,329 Quest Diagnostics shares in Q1 2024, an estimated $597K.
  • Philadelphia Trust Company first reported a position in Quest Diagnostics in Q2 2013 and held it in 43 quarters.
  • Philadelphia Trust Company's Quest Diagnostics position peaked at $26.4M in Q1 2016.
  • 818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Philadelphia Trust Company's 13F filing for Q1 2024, filed 13 May 2024.